Published: May 12, 2021
Transparency Market Research (TMR) has published a new report titled, “
Pneumococcal Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global pneumococcal vaccines market was valued at US$ 7,247.6 Mn in 2017 and is anticipated expand at a CAGR of 3.3% from 2018 to 2026. Increase in patient pool, growth of the pharmaceutical industry, government initiatives to increase vaccination programs, rise in health care expenditure, and surge in product approvals are projected to augment the global market from 2018 to 2026.
Request Brochure of Report -
Increase in Government Participation in Design & Implementation of Comprehensive Vaccination Programs to Propel Market
WHO lists Sinopharm’s COVID-19 vaccine for emergency use
1
The inactivated Vero Cell COVID-19 vaccine is now eligible for global rollout alongside the four other vaccines with World Health Organization Emergency Use Listing.
The World Health Organization (WHO) has listed Sinopharm’s Vero Cell COVID-19 vaccine for emergency use, allowing it to be rolled out globally. Vero Cell is produced by Beijing Bio-Institute of Biological Products Co Ltd, a subsidiary of China National Biotec Group (CNBG).
“The addition of this vaccine has the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk,” commented Dr Mariângela Simão, WHO Assistant-Director General for Access to Health Products. “We urge the manufacturer to participate in the COVAX Facility and contribute to the goal of more equitable vaccine distribution.”
The Centre has informed the Supreme Court that no governmental aid, assistance or grant was made either for research or development of COVID-19 vaccines - Covaxin and Covishield - but some financial assistance was given for conducting clinical trials. In an affidavit filed in the apex court on Sunday night, the Centre has said that Covaxin has been developed under public private partnership between the Indian Council of Medical Research (ICMR) and Bharat Biotech International Ltd (BBIL). ICMR has not provided any funds to BBIL for Covaxin development. However, funds have been spent in various activities undertaken by ICMR-NIV, Pune for Covaxin development. Also phase 3 clinical trials of Covaxin have been funded by ICMR. The trials have been conducted at 22 sites in 25,800 participants, the affidavit said, adding that total estimated expenditure of ICMR in this was 35 crore.
NEW DELHI: The Centre has informed the Supreme Court that no governmental aid, assistance or grant was made either for research or development of Covid-19 vaccines - Covaxin and Covishield - but some financial assistance was given for conducting clinical trials.
In an affidavit filed in the apex court on Sunday night, the Centre has said that Covaxin has been developed under public private partnership between the Indian Council of Medical Research (ICMR) and Bharat Biotech International Ltd (BBIL).
“ICMR has not provided any funds to BBIL for Covaxin development. However, funds have been spent in various activities undertaken by ICMR-NIV, Pune for Covaxin development. Also phase 3 clinical trials of Covaxin have been funded by ICMR. The trials have been conducted at 22 sites in 25,800 participants,” the affidavit said, adding that total estimated expenditure of ICMR in this was 35 crore.
Gave some financial aid for Covaxin, Covishield trials, not R&D: Govt
By IANS |
Published on
Mon, May 10 2021 22:27 IST |
7 Views
Bharat Biotech gets permission to manufacture Covaxin for sale (Lead, correcting para 1) . Image Source: IANS News
New Delhi, May 10 : The Centre has told the Supreme Court that no governmental aid, assistance or grant was made either for research or development of either Covaxin or Covishield vaccines but some financial assistance was given for conducting clinical trials.
In an affidavit, the Centre said that Covaxin has been developed under public private partnership (PPP) between the Indian Council of Medical Research (ICMR) and Bharat Biotech International Ltd (BBIL). The PPP was executed under a formal MoU between the ICMR and the BBIL which includes a 5 per cent royalty clause for the ICMR on net sales and other clauses like prioritisation of in-country supplies, and the product intellectual property rights are shared